All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment in R/R MF?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What is the long-term benefit of momelotinib treatment in relapsed/refractory myelofibrosis (MF)?

JAK inhibition has made a significant impact on patients with MF. Momelotinib is a JAK1/2 and ACVR1 inhibitor, which improves anemia and most importantly survival. Mesa also mentions the JAK inhibitor pipeline and which inhibitors will soon become available, offering more treatment options.